DEF: Apyx Medical Prepares for 2025 Annual Meeting Amidst Financial Headwinds and Strategic Restructuring

Apyx Medical Corporation announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and a critical amendment to its Certificate of Incorporation tied to a credit agreement, following a year of decreased revenue and increased operating losses.

Summary

• Apyx Medical Corporation will hold its 2025 Annual Meeting of Stockholders on August 7, 2025, to vote on five key proposals.
• The proposals include the election of five directors, ratification of RSM US LLP as the independent auditor for fiscal year 2025, and advisory votes on named executive officer compensation and its frequency (Board recommends every three years).
• A significant proposal is the approval of an amendment to the Company's Certificate of Incorporation to remove a creditor compromise provision, which is required by the Perceptive Credit Agreement to avoid default.
• For the fiscal year ended December 31, 2024, total revenue decreased by 8.1% year-over-year to $48.1 million, with Advanced Energy revenue declining 11.0% to $38.6 million.
• The company reported an increased loss from operations of $18.8 million in 2024, compared to $17.3 million in 2023.
• In November 2024, Apyx Medical undertook a cost-saving restructuring, reducing its U.S. workforce by nearly 25%, expecting annualized future cost savings of approximately $4.3 million.
• The company eliminated executive bonuses in 2024, reduced the Board of Directors from eight to five members, and cut aggregate board cash compensation from $0.5 million to $0.1 million annually, while increasing stock-based compensation.
• Apyx Medical anticipates reducing annual operating expenses below $40 million in 2025 through identified cost savings in professional fees, R&D, credit card fees, and stock-based compensation.
• On November 7, 2024, the company amended its Perceptive Credit Agreement, which included reduced revenue targets for its Advanced Energy segment and introduced a maximum operating expense financial covenant.
• The company closed a $7.0 million registered direct offering on November 7, 2024, issuing 3,000,000 common shares and 2,934,690 pre-funded warrants.
• On May 13, 2025, Apyx Medical received 510(k) clearance from the FDA for its AYON Body Contouring System, with commercial launch planned for the second half of 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed outlook. While there are significant negatives in past financial performance (decreased revenue, increased losses), the company is actively implementing strategic cost-saving measures, has secured new financing, and received FDA clearance for a new product (AYON) with a planned launch. The necessity of a Certificate of Incorporation amendment due to a credit agreement covenant is a notable negative. The overall sentiment is cautious, reflecting challenges but also proactive steps towards improvement.

Positives

• The company received 510(k) clearance from the FDA for its AYON Body Contouring System on May 13, 2025, with commercial launch anticipated in the second half of 2025, indicating new product innovation and market entry.
• Apyx Medical implemented significant cost-saving measures in November 2024, including a nearly 25% reduction in its U.S. workforce, expected to yield approximately $4.3 million in annualized savings.
• The company eliminated executive bonuses in 2024 and reduced Board size and cash compensation, demonstrating a commitment to expense control and cash preservation.
• Management projects total annual operating expenses to fall below $40 million in 2025 due to identified cost savings, aiming for decreased loss and cash-flow breakeven.
• The Perceptive Credit Agreement was amended to reduce financial covenant revenue targets and introduce operating expense covenants, providing more achievable financial benchmarks.
• The company successfully completed a $7.0 million registered direct offering, strengthening its financial position.

Negatives

• Total revenue for 2024 decreased by 8.1% year-over-year to $48.1 million, indicating a decline in sales performance.
• Advanced Energy revenue, a key segment, decreased by 11.0% year-over-year to $38.6 million.
• Loss from operations increased to $18.8 million in 2024 from $17.3 million in 2023, reflecting worsening operational profitability.
• The company incurred approximately $0.6 million in pre-tax charges in Q4 2024 primarily for severance and employee termination benefits due to the reduction in force.
• Executive bonuses were eliminated in 2024, which could impact employee morale and retention, despite being a cost-saving measure.
• The requirement to amend the Certificate of Incorporation to remove the creditor compromise provision is a condition of the Perceptive Credit Agreement, indicating past financial distress or a need to align with lender terms.

Risks

• Failure to approve the Creditor Compromise Amendment would result in the Company defaulting under the Perceptive Credit Agreement, which could have severe financial consequences.
• The company must maintain a balance of $3.0 million in cash and cash equivalents during the term of the Perceptive Credit Agreement, posing a liquidity risk if not managed effectively.
• The success of the AYON Body Contouring System commercial launch in H2 2025 is critical for future revenue growth, and any delays or poor market reception could negatively impact financial performance.
• Economic uncertainty for capital equipment purchases in the aesthetics space could continue to impact revenue generation.
• The company's ability to achieve projected cost savings and reduce annual operating expenses below $40 million in 2025 is crucial for reaching cash-flow breakeven, and failure to do so poses a financial risk.

Future Outlook

Apyx Medical plans a commercial launch of its newly FDA-cleared AYON Body Contouring System with key surgeons in critical geographies starting in the second half of 2025. The company also intends to expand the cleared indications for AYON, including power liposuction, with an additional 510(k) submission later in 2025. Management anticipates reducing annual operating expenses below $40 million in 2025 through various cost-saving initiatives, aiming to decrease losses and achieve cash-flow breakeven. The company's Perceptive Credit Agreement includes future revenue targets for its Advanced Energy segment, reaching $60.3 million by 2027, and sets maximum operating expense targets for 2025 and 2026.

Management Comments

• The Board unanimously recommends voting FOR the Board's nominees for the Director Proposal, FOR the Auditor Proposal, FOR the Say-on-Pay Proposal, THREE YEARS for the Frequency Proposal, and FOR the Creditor Compromise Amendment.
• The Board believes Mr. Vizirgianakis is best suited for leading discussions, at the Board level, regarding performance relative to our corporate strategy.
• The Board believes that risk management is an important component of the Company's corporate strategy.
• The Compensation Committee believes that the tax deduction limitation should not compromise its ability to structure compensation programs that provide benefits to the Company that outweigh the potential benefit of a tax deduction and, therefore, may approve compensation that is not deductible for tax purposes.
• The Board of Directors believes that it is in the Company's best interests to approve and adopt the Creditor Compromise Amendment.

Industry Context

Apyx Medical operates in the advanced energy technology and medical device industry, specifically targeting cosmetic and hospital surgical markets with its Renuvion and J-Plasma products. The launch of the AYON Body Contouring System positions the company to compete in the evolving aesthetic surgery market, which is increasingly seeking integrated and versatile solutions. The reported decline in revenue and increased operating losses suggest challenges within its current market segments, possibly reflecting broader economic uncertainties impacting capital equipment purchases in the aesthetics space. The strategic focus on cost savings and a new product launch indicates an effort to adapt to market conditions and regain competitive footing, aligning with a trend of medical device companies seeking efficiency and innovation to drive growth.

Management Changes

Corporate Governance

Related Party Transactions

• Teodora Shileva, spouse of Nikolay Shilev (Apyx Bulgaria's Managing Director), is an employee in the accounting department.
• Svetoslav Shilev, son of Nikolay Shilev (Apyx Bulgaria's Managing Director), is a quality manager in the quality assurance department.
• The company has a policy requiring authorization from the appropriate department executive manager for related party transactions up to $120,000, and referral to the Audit Committee and Board for transactions exceeding this amount.

Stakeholder Impact

• **Shareholders**: Will vote on key governance matters, including director elections, auditor ratification, executive compensation, and a critical amendment to the Certificate of Incorporation that impacts the company's credit agreement. The $7.0 million capital raise and increased stock-based compensation for the board aim to align interests and provide capital, but the decline in revenue and increased losses may concern investors.
• **Employees**: Experienced a nearly 25% reduction in the U.S. workforce as part of a cost-saving restructuring, leading to severance payments for those affected. Executive bonuses were eliminated in 2024. These actions could impact morale and retention for remaining employees.
• **Customers**: The FDA clearance and planned commercial launch of the AYON Body Contouring System in H2 2025 could offer new and advanced treatment options, potentially enhancing customer satisfaction and market reach.
• **Creditors (Perceptive Credit Holdings IV, LP)**: The amendment to the Perceptive Credit Agreement and the requirement for stockholder approval of the Creditor Compromise Amendment directly impact the company's relationship with its lender, ensuring compliance with financial covenants and maintaining access to credit.
• **Management**: Executive compensation was adjusted, with bonuses eliminated in 2024, but equity awards continue to be a key component. The restructuring and cost-saving initiatives place pressure on management to improve financial performance and achieve cash-flow breakeven.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on August 7, 2025, to vote on proposed matters.
• Mail a notice of internet availability of proxy materials to stockholders on or about June 27, 2025.
• Commercial launch of the AYON Body Contouring System with key surgeons in critical geographies starting in the second half of 2025.
• Submit an additional 510(k) for AYON later this year to expand cleared indications to include power liposuction.
• Achieve annual operating expenses below $40 million in 2025 through identified cost savings.
• File a Current Report on Form 8-K with the SEC within four business days following the Annual Meeting to publish voting results.
• Consider the outcome of the Say-on-Pay advisory vote in determining future compensation policies.
• The Board may decide to hold a non-binding advisory vote on future compensation of future Named Executive Officers more or less frequently than the option voted by stockholders.
• If approved by stockholders and not abandoned by the Board, the Creditor Compromise Amendment would become effective as soon as reasonably practicable after the Meeting by filing a Certificate of Amendment with the Delaware Secretary of State.

Key Dates

Recommendation

Keywords

Medical Device, Aesthetic Surgery, Body Contouring, Renuvion, J-Plasma, Helium Plasma Technology, FDA Clearance, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Restructuring, Cost Savings, Capital Raise, Credit Agreement, Shareholder Meeting